Keywords
Last Name
Institution

Doris Germain

TitleASSOCIATE PROFESSOR
InstitutionMount Sinai
DepartmentHematology and Medical Oncology
Address

     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Giugliani R, Waldek S, Germain DP, Nicholls K, Bichet DG, Simosky JK, Bragat AC, Castelli JP, Benjamin ER, Boudes PF. A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects. Mol Genet Metab. 2013 May; 109(1):86-92.
      View in: PubMed
    2. Hatami R, Sieuwerts AM, Izadmehr S, Yao Z, Qiao RF, Papa L, Look MP, Smid M, Ohlssen J, Levine AC, Germain D, Burstein D, Kirschenbaum A, DiFeo A, Foekens JA, Narla G. KLF6-SV1 drives breast cancer metastasis and is associated with poor survival. Sci Transl Med. 2013 Jan 23; 5(169):169ra12.
      View in: PubMed
    3. Adelson K, Germain D, Raptis G, Biran N. Hormonal modulation in the treatment of breast cancer. Endocrinol Metab Clin North Am. 2011 Sep; 40(3):519-32, viii.
      View in: PubMed
    4. Chander H, Halpern M, Resnick-Silverman L, Manfredi JJ, Germain D. Skp2B overexpression alters a prohibitin-p53 axis and the transcription of PAPP-A, the protease of insulin-like growth factor binding protein 4. PLoS One. 2011; 6(8):e22456.
      View in: PubMed
    5. Germain D. Estrogen carcinogenesis in breast cancer. Endocrinol Metab Clin North Am. 2011 Sep; 40(3):473-84, vii.
      View in: PubMed
    6. Papa L, Germain D. Estrogen receptor mediates a distinct mitochondrial unfolded protein response. J Cell Sci. 2011 May 1; 124(Pt 9):1396-402.
      View in: PubMed
    7. Misra D, Xie W, Regan MM, Ross RW, Lee GS, Germain D, Kantoff PW, Oh WK. Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy. BJU Int. 2011 Oct; 108(7):1086-91.
      View in: PubMed
    8. Ishii Y, Papa L, Bahadur U, Yue Z, Aguirre-Ghiso J, Shioda T, Waxman S, Germain D. Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response. Clin Cancer Res. 2011 Apr 15; 17(8):2292-300.
      View in: PubMed
    9. Germain D. Skp2 and Skp2B team up against Rb and p53. Cell Div. 2011; 6(1):1.
      View in: PubMed
    10. Lacombe D, Germain DP, Papaxanthos-Roche A. [Azoospermia as a new feature of Fabry disease]. Rev Med Interne. 2010 Dec; 31 Suppl 2:S214-6.
      View in: PubMed
    11. Malinvaud D, Germain DP, Benistan K, Bonfils P. [Vestibular and cochlear manifestations in Fabry's disease]. Rev Med Interne. 2010 Dec; 31 Suppl 2:S251-6.
      View in: PubMed
    12. Germain DP, Boucly C, Carlier RY, Caudron E, Charlier P, Colas F, Jabbour F, Martinez V, Mokhtari S, Orlikowski D, Pellegrini N, Perronne C, Prigent H, Rubinsztajn R, Benistan K. [Enzyme replacement therapy of lysosomal storage diseases]. Rev Med Interne. 2010 Dec; 31 Suppl 2:S279-91.
      View in: PubMed
    13. Germain DP. [Third French multidisciplinary meeting on Fabry disease]. Rev Med Interne. 2010 Dec; 31 Suppl 2:S205-8.
      View in: PubMed
    14. Caudron E, Germain DP, Prognon P. [Fabry disease: enzymatic screening using dried blood spots on filter paper]. Rev Med Interne. 2010 Dec; 31 Suppl 2:S263-9.
      View in: PubMed
    15. Germain DP, Benistan K, Angelova L. X-linked inheritance and its implication in the diagnosis and management of female patients in Fabry disease. Rev Med Interne. 2010 Dec; 31 Suppl 2:S209-13.
      View in: PubMed
    16. Mehta A, Beck M, Eyskens F, Feliciani C, Kantola I, Ramaswami U, Rolfs A, Rivera A, Waldek S, Germain DP. Fabry disease: a review of current management strategies. QJM. 2010 Sep; 103(9):641-59.
      View in: PubMed
    17. Chander H, Halpern M, Resnick-Silverman L, Manfredi JJ, Germain D. Skp2B attenuates p53 function by inhibiting prohibitin. EMBO Rep. 2010 Mar; 11(3):220-5.
      View in: PubMed
    18. Germain DP, Fan JQ. Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies. Int J Clin Pharmacol Ther. 2009; 47 Suppl 1:S111-7.
      View in: PubMed
    19. Germain D. Ubiquitin-dependent and -independent mitochondrial protein quality controls: implications in ageing and neurodegenerative diseases. Mol Microbiol. 2008 Dec; 70(6):1334-41.
      View in: PubMed
    20. Radke S, Chander H, Schäfer P, Meiss G, Krüger R, Schulz JB, Germain D. Mitochondrial protein quality control by the proteasome involves ubiquitination and the protease Omi. J Biol Chem. 2008 May 9; 283(19):12681-5.
      View in: PubMed
    21. Matsuzaki Y, Koyama M, Hitomi T, Yokota T, Kawanaka M, Nishikawa A, Germain D, Sakai T. Arctiin induces cell growth inhibition through the down-regulation of cyclin D1 expression. Oncol Rep. 2008 Mar; 19(3):721-7.
      View in: PubMed
    22. Ishii Y, Waxman S, Germain D. Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3. Cancer Res. 2008 Feb 1; 68(3):852-60.
      View in: PubMed
    23. Germain D, Frank DA. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res. 2007 Oct 1; 13(19):5665-9.
      View in: PubMed
    24. Mistry P, Germain DP. [Therapeutic objectives in Gaucher disease]. Rev Med Interne. 2007 Oct; 28 Suppl 2:S171-5.
      View in: PubMed
    25. Umanskaya K, Radke S, Chander H, Monardo R, Xu X, Pan ZQ, O'Connell MJ, Germain D. Skp2B stimulates mammary gland development by inhibiting REA, the repressor of the estrogen receptor. Mol Cell Biol. 2007 Nov; 27(21):7615-22.
      View in: PubMed
    26. Magage S, Lubanda JC, Susa Z, Bultas J, Karetová D, Dobrovolný R, Hrebícek M, Germain DP, Linhart A. Natural history of the respiratory involvement in Anderson-Fabry disease. J Inherit Metab Dis. 2007 Oct; 30(5):790-9.
      View in: PubMed
    27. Ishii Y, Waxman S, Germain D. Targeting the ubiquitin-proteasome pathway in cancer therapy. Anticancer Agents Med Chem. 2007 May; 7(3):359-65.
      View in: PubMed
    28. Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, Breunig F, Charrow J, Germain DP, Nicholls K, Banikazemi M. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007 Apr; 30(2):184-92.
      View in: PubMed
    29. Ishii Y, Pirkmaier A, Alvarez JV, Frank DA, Keselman I, Logothetis D, Mandeli J, O'Connell MJ, Waxman S, Germain D. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. J Natl Cancer Inst. 2006 Sep 6; 98(17):1238-47.
      View in: PubMed
    30. Roy S, Touboul D, Brunelle A, Germain DP, Prognon P, Laprévote O, Chaminade P. [Imaging mass spectrometry: a new tool for the analysis of skin biopsy. Application in Fabry's disease]. Ann Pharm Fr. 2006 Sep; 64(5):328-34.
      View in: PubMed
    31. Clavelou P, Besson G, Elziere C, Ferrier A, Pinard JM, Hermier M, Artigou JY, Germain DP. [Neurological aspects of Fabry's disease]. Rev Neurol (Paris). 2006 May; 162(5):569-80.
      View in: PubMed
    32. Mistry P, Germain DP. Therapeutic goals in Gaucher disease. Rev Med Interne. 2006 Mar; 27 Suppl 1:S30-8.
      View in: PubMed
    33. Mistry P, Germain DP. Phenotype variations in Gaucher disease. Rev Med Interne. 2006 Mar; 27 Suppl 1:S3-10.
      View in: PubMed
    34. Malinvaud D, Avan P, Germain DP, Benistan K, Bonfils P. [The cochlea in Fabry disease: a sensorineural hearing loss model of vascular origin?]. Rev Med Interne. 2006 Jul; 27(7):527-31.
      View in: PubMed
    35. Radke S, Pirkmaier A, Germain D. Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer. Oncogene. 2005 May 12; 24(21):3448-58.
      View in: PubMed
    36. Roy S, Gaudin K, Germain DP, Baillet A, Prognon P, Chaminade P. Optimisation of the separation of four major neutral glycosphingolipids: application to a rapid and simple detection of urinary globotriaosylceramide in Fabry disease. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jun 15; 805(2):331-7.
      View in: PubMed
    37. Benzeno S, Narla G, Allina J, Cheng GZ, Reeves HL, Banck MS, Odin JA, Diehl JA, Germain D, Friedman SL. Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res. 2004 Jun 1; 64(11):3885-91.
      View in: PubMed
    38. Pirkmaier A, Dow R, Ganiatsas S, Waring P, Warren K, Thompson A, Hendley J, Germain D. Alternative mammary oncogenic pathways are induced by D-type cyclins; MMTV-cyclin D3 transgenic mice develop squamous cell carcinoma. Oncogene. 2003 Jul 10; 22(28):4425-33.
      View in: PubMed
    39. Pirkmaier A, Yuen K, Hendley J, O'Connell MJ, Germain D. Cyclin d1 overexpression sensitizes breast cancer cells to fenretinide. Clin Cancer Res. 2003 May; 9(5):1877-84.
      View in: PubMed
    40. Senechal M, Germain DP. Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients. Clin Genet. 2003 Jan; 63(1):46-52.
      View in: PubMed
    41. Boutouyrie P, Laurent S, Laloux B, Lidove O, Grunfeld JP, Germain DP. Arterial remodelling in Fabry disease. Acta Paediatr Suppl. 2002; 91(439):62-6.
      View in: PubMed
    42. Demuth K, Germain DP. Endothelial markers and homocysteine in patients with classic Fabry disease. Acta Paediatr Suppl. 2002; 91(439):57-61.
      View in: PubMed
    43. Boutouyrie P, Laurent S, Laloux B, Lidove O, Grunfeld JP, Germain DP. Non-invasive evaluation of arterial involvement in patients affected with Fabry disease. J Med Genet. 2001 Sep; 38(9):629-31.
      View in: PubMed
    44. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ. Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease. N Engl J Med. 2001 Jul 5; 345(1):9-16.
      View in: PubMed
    45. Germain DP. Pseudoxanthoma elasticum: evidence for the existence of a pseudogene highly homologous to the ABCC6 gene. J Med Genet. 2001 Jul; 38(7):457-61.
      View in: PubMed
    46. Germain DP. Co-occurrence and contribution of Fabry disease and Klippel-Trénaunay-Weber syndrome to a patient with atypical skin lesions. Clin Genet. 2001 Jul; 60(1):63-7.
      View in: PubMed
    47. Germain DP, Salard D, Fellmann F, Azibi K, Caillaud C, Bernard MC, Poenaru L. Identification of a novel de novo mutation (G373D) in the alpha-galactosidase A gene (GLA) in a patient affected with Fabry disease. Hum Mutat. 2001 Apr; 17(4):353.
      View in: PubMed
    48. Germain DP. A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant. Contrib Nephrol. 2001; (136):234-40.
      View in: PubMed
    49. Germain DP. [Fabry disease. Clinical and genetic aspects. Therapeutic perspectives]. Rev Med Interne. 2000 Dec; 21(12):1086-103.
      View in: PubMed
    50. Germain DP, Poenaru L. Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches. Biochem Biophys Res Commun. 1999 Apr 21; 257(3):708-13.
      View in: PubMed
    Germain's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067